New Zealand markets close in 2 hours 41 minutes

BIIB Jan 2025 310.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
102.500.00 (0.00%)
As of 10:33AM EDT. Market open.
Full screen
Previous close102.50
Open102.50
Bid91.40
Ask100.20
Strike310.00
Expiry date2025-01-17
Day's range102.50 - 102.50
Contract rangeN/A
Volume2
Open interest2
  • Zacks

    Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News

    Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.

  • Zacks

    Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

    Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.

  • Reuters

    Biogen in up to $1.8 billion deal as rare diseases take center stage

    Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ. The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.